BioPorto Diagnostics is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is a significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship product is The NGAL Test™, which is designed to aid in the risk assessment of acute kidney injury (AKI), a common clinical syndrome that can have severe consequences if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in several countries worldwide, and For Research Use Only in the US.
BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. BioPorto A/S shares are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.